NEXT MEDICAL PRODUCTS COMPANY – Trademark Portfolio
Entity Type: 16
NEXT MEDICAL PRODUCTS COMPANY holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 4 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 3 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include LITHOCLEAR, CLEAR IMAGE, and CLEAR IMAGE SINGLES. The owner is based in Branchburg, NJ.
45 Columbia Rd.
Branchburg, NJ 08876
Showing of trademarks Trademarks
Trademark Classifications
NEXT MEDICAL PRODUCTS COMPANY's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Frequently Asked Questions
How many trademarks does NEXT MEDICAL PRODUCTS COMPANY have?
NEXT MEDICAL PRODUCTS COMPANY has 6 U.S. trademarks filed with the USPTO. Of these, 3 registered, 3 cancelled.
What trademark classes does NEXT MEDICAL PRODUCTS COMPANY file in?
NEXT MEDICAL PRODUCTS COMPANY files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 1 (Chemicals), Class 10 (Medical Apparatus). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are NEXT MEDICAL PRODUCTS COMPANY's most well-known trademarks?
NEXT MEDICAL PRODUCTS COMPANY's registered trademark portfolio includes well-known marks such as LITHOCLEAR, CLEAR IMAGE, and CLEAR IMAGE SINGLES. These are among 3 currently registered trademarks in the portfolio.
What is NEXT MEDICAL PRODUCTS COMPANY's trademark registration success rate?
NEXT MEDICAL PRODUCTS COMPANY has a 50% trademark registration rate, with 3 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.